Cochrane Abstracts
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Optimisation of Chemotherapy and Radiotherapy for Untreated Hodgkin Lymphoma Patients With Respect to Second Malignant Neoplasms, Overall and Progression‐free Survival: Individual Participant Data Analysis." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437455/all/Optimisation_of_chemotherapy_and_radiotherapy_for_untreated_Hodgkin_lymphoma_patients_with_respect_to_second_malignant_neoplasms__overall_and_progression‐free_survival:_individual_participant_data_analysis.
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437455/all/Optimisation_of_chemotherapy_and_radiotherapy_for_untreated_Hodgkin_lymphoma_patients_with_respect_to_second_malignant_neoplasms__overall_and_progression‐free_survival:_individual_participant_data_analysis. Accessed March 24, 2025.
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437455/all/Optimisation_of_chemotherapy_and_radiotherapy_for_untreated_Hodgkin_lymphoma_patients_with_respect_to_second_malignant_neoplasms__overall_and_progression‐free_survival:_individual_participant_data_analysis
Optimisation of Chemotherapy and Radiotherapy for Untreated Hodgkin Lymphoma Patients With Respect to Second Malignant Neoplasms, Overall and Progression‐free Survival: Individual Participant Data Analysis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437455/all/Optimisation_of_chemotherapy_and_radiotherapy_for_untreated_Hodgkin_lymphoma_patients_with_respect_to_second_malignant_neoplasms__overall_and_progression‐free_survival:_individual_participant_data_analysis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis
ID - 437455
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437455/all/Optimisation_of_chemotherapy_and_radiotherapy_for_untreated_Hodgkin_lymphoma_patients_with_respect_to_second_malignant_neoplasms__overall_and_progression‐free_survival:_individual_participant_data_analysis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
